| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T36 |
0-13 |
Sentence |
denotes |
Statement no. |
| T37 |
14-23 |
Sentence |
denotes |
Statement |
| T38 |
24-406 |
Sentence |
denotes |
1 In outpatients with new-onset diarrhea, ascertain information about high-risk contact exposure; obtain a detailed history of symptoms associated with COVID-19, including fever, cough, shortness of breath, chills, muscle pain, headache, sore throat, or new loss of taste or smell; and obtain a thorough history for other Gl symptoms, including nausea, vomiting, and abdominal pain. |
| T39 |
407-616 |
Sentence |
denotes |
2 In outpatients with new-onset Gl symptoms (eg, nausea, vomiting, abdominal pain, and diarrhea), monitor for symptoms associated with COVID-19, as GI symptoms may precede COVID-related symptoms by a few days. |
| T40 |
617-694 |
Sentence |
denotes |
In a high COVID-19 prevalence setting, COVID-19 testing should be considered. |
| T41 |
695-908 |
Sentence |
denotes |
3 In hospitalized patients with suspected or known COVID-19, obtain a thorough history of GI symptoms (ie, nausea, vomiting, abdominal pain, and diarrhea), including onset, characteristics, duration, and severity. |
| T42 |
909-1052 |
Sentence |
denotes |
4 There is presently inadequate evidence to support stool testing for diagnosis or monitoring of COVID-19 as part of routine clinical practice. |
| T43 |
1053-1193 |
Sentence |
denotes |
5 In patients (outpatients or inpatients) with elevated LFTs in context of suspected or known COVID-19, evaluate for alternative etiologies. |
| T44 |
1194-1419 |
Sentence |
denotes |
6 In hospitalized patients with suspected or known COVID-19, obtain baseline LFTs at the time of admission and consider LFT monitoring throughout the hospitalization, particularly in the context of drug treatment for COVID-19 |
| T45 |
1420-1549 |
Sentence |
denotes |
7 In hospitalized patients undergoing drug treatment for COVID-19, evaluate for treatment-related Gl and hepatic adverse effects. |
